ASH 2021 | Changes in myeloma treatment following implementation of the IMWG criteria
Efstathios Kastritis
• 11 Dec 2021
In this video, Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, shares some findings on an analysis that aimed to evaluate how the treatment of previously asymptomatic myeloma patients changed following the implementation of the 2014 IMWG criteria. Dr Kastritis explains how the use of the ‘biomarkers of malignancy’ criterion impacted the eligibility of patients who could start therapy, and how this is a step forward for the myeloma community. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
